ANDA 88135, held by Chartwell Rx. Thioridazine Hydrochloride.
As of Nov 16, 2026, ANDA 88135 (Thioridazine Hydrochloride), held by Chartwell Rx, was first approved by FDA on Nov 20, 1984, with 25 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Thioridazine is indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 20, 1984 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Thioridazine Hydrochloride100MG · tablet;oral | Thioridazine Hydrochloride | Discontinued |
| Jan 22, 2025 | Supplement 36Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 35Labeling · Standard review | Approved | None posted |
| Apr 19, 2016 | Supplement 34Labeling | Approved | None posted |
| Sep 5, 2002 | Supplement 29Labeling | Approved | None posted |
| May 8, 2002 | Supplement 28Manufacturing | Approved | None posted |
| Aug 14, 2001 | Supplement 25Labeling | Approved | None posted |
| Apr 12, 2001 | Supplement 27Manufacturing | Approved | None posted |
| Feb 21, 2001 | Supplement 26Manufacturing | Approved | None posted |
| May 5, 1999 | Supplement 23Manufacturing | Approved | None posted |
| Oct 20, 1998 | Supplement 21Labeling | Approved | None posted |
| Oct 20, 1998 | Supplement 20Manufacturing | Approved | None posted |
| Sep 18, 1998 | Supplement 22Manufacturing | Approved | None posted |
| Mar 21, 1995 | Supplement 19Manufacturing | Approved | None posted |
| Jan 9, 1990 | Supplement 18Labeling | Approved | None posted |
| Sep 28, 1989 | Supplement 17Labeling | Approved | None posted |
| Nov 10, 1988 | Supplement 16Manufacturing | Approved | None posted |
| Jul 15, 1987 | Supplement 13Manufacturing | Approved | None posted |
| Jul 15, 1987 | Supplement 12Manufacturing | Approved | None posted |
| Jul 15, 1987 | Supplement 11Manufacturing | Approved | None posted |
| Jan 15, 1987 | Supplement 10Manufacturing | Approved | None posted |
| Aug 29, 1986 | Supplement 7Manufacturing | Approved | None posted |
| Apr 18, 1986 | Supplement 8Manufacturing | Approved | None posted |
| Apr 30, 1985 | Supplement 4Manufacturing | Approved | None posted |
| Apr 30, 1985 | Supplement 3Manufacturing | Approved | None posted |
| Apr 30, 1985 | Supplement 2Manufacturing | Approved | None posted |
| Nov 20, 1984 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters